Johnson & Johnson highlights 48-week Crohn’s perianal fistula results for TREMFYA in FUZION trial

Johnson & Johnson said it is advancing new evidence for its inflammatory disease drug TREMFYA (guselkumab), pointing to results from its Phase 3 FUZION study that tracked perianal fistula outcomes in adults with Crohn’s disease. In an announcement dated Oct. 19, the company said the latest reporting covers one year of data and focuses on whether patients maintained or improved fistula remission through 48 weeks.

The company’s update centers on durability of response, a measure intended to show that benefits persist beyond early treatment. According to the company’s description of the study outcomes, TREMFYA maintained or improved fistula remission through the 48-week point in the trial population.

Johnson & Johnson also framed the results as differentiating within the drug class. The announcement said TREMFYA is the only IL-23 treatment that delivers durable fistula remission through 48 weeks, referencing the company’s interpretation of comparative data within the IL-23 category.

The TREMFYA program is tied to guselkumab, an IL-23 (interleukin-23) inhibitor. IL-23 inhibitors are designed to interfere with immune indicating associated with chronic inflammation. For Crohn’s disease, and especially for perianal fistulas, treatments are often judged by both clinical improvement and whether remission lasts over time.

Perianal fistulas represent a difficult-to-treat form of Crohn’s disease. The presence of fistulas can require ongoing management because symptoms can recur and complications can affect quality of life. By highlighting 48-week outcomes, Johnson & Johnson is emphasizing a time horizon that may be important to clinicians evaluating sustained disease control rather than short-term response.

The company’s announcement described the FUZION study as a Phase 3 trial and said the reported outcomes extend through a 48-week window, with “one-year results” used to characterize the duration of follow-up. It did not, in the brief market item, provide additional operational details such as enrollment size, dosing regimens, primary endpoints wording, or subgroup findings.

The announcement also did not provide, in the text available in the market report, the magnitude of the effect such as exact remission percentages, response rates, or statistical significance levels. It similarly did not describe safety findings at the 48-week mark, including rates of adverse events, serious infections, or discontinuations.

With fewer details disclosed in the published market item, investors and clinicians will likely look for fuller clinical materials, such as a conference presentation or full prescribing information updates, to understand the precision of the results and how durable remission was defined and assessed in FUZION. Until those additional disclosures are available, the headline takeaway remains that Johnson & Johnson is emphasizing persistence of perianal fistula remission over 48 weeks for TREMFYA in Crohn’s disease, supported by the company’s Phase 3 data framing.